Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 2Terminated 2Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 16Recurrence 2Lymphoma, Non-Hodgkin 2Smoldering Multiple Myeloma 1Renal Insufficiency 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms 1Lymphoma 1Leukemia, Plasma Cell 1Hodgkin Disease 1Hematologic Neoplasms 1

Interventions

pembrolizumab 38Blood Specimen Collection 38Bevacizumab 22Surveys and Questionnaires 18Standard of Care 18Radiotherapy 17Exercise 17Carboplatin 17Nivolumab 15atezolizumab 14Paclitaxel 14Cisplatin 14Drug Therapy 13Fluorouracil 12Cyclophosphamide 12Cetuximab 11Trastuzumab 10Pemetrexed 10Leucovorin 10Docetaxel 10Dexamethasone 10Oxaliplatin 9Biopsy 9pertuzumab 8olaparib 8Temozolomide 8Panitumumab 8Observation 8Irinotecan 8abemaciclib 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Neoplasms × isatuximab × Clear all
NCT05145400 2025-09-26

Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma

UNC Lineberger Comprehensive Cancer Center

Phase 2 Recruiting
50 enrolled
Plasma cell

Multiple Myeloma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡